Venture Life Group PLC acquires OrganiCare Nature's Sciences, LLC for USD 28,000,000 (2026)

Deal facts

Buyer: Venture Life Group PLC
Target: OrganiCare Nature's Sciences, LLC
Deal value: USD 28,000,000
Announced: 3 June 2026
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash, deferred

Sources

What we know

Venture Life Group PLC has agreed to acquire OrganiCare Nature's Sciences, LLC in a strategic acquisition valued at USD 28 million. The transaction involves a mixed consideration structure comprising cash and deferred payments. This deal brings together a UK-based public company with an American healthcare business, expanding the buyer's footprint in the sector. The announcement was made on 3 June 2026, marking a significant step in the consolidation of the healthcare industry.

The deal is now reported as completed, indicating that all necessary conditions have been satisfied. While specific regulatory details remain unreported, the completion status suggests the transaction has successfully concluded. The acquisition allows the management team to integrate the target's operations into the existing portfolio. No further regulatory hurdles are currently anticipated given the final status. The transaction represents a substantial investment in the US healthcare market by a British entity.

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

3 Jun 2026CompletedClosed
Acquisition of FemiClear and CUROXEN
Disclaimer* THIS ANNOUNCEMENT WAS DEEMED BY THE COMPANY TO CONTAIN INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. WITH THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. 3 June 2026 VENTURE LIFE
LSE RNS

OpinionExit Mode editorial

We see a clear signal in the cross-border movement of Venture Life Group PLC acquiring OrganiCare Nature's Sciences, LLC. This completed strategic acquisition, announced on 3 June 2026, moves a US healthcare asset into the UK public sphere for a total consideration of 28 million USD. The deal structure mixes immediate cash with deferred payments, a common mechanic when bridging valuation gaps between private sellers and public buyers. For the SME founder reading this, the mix of cash and deferred value is often the most critical commercial term to negotiate, as it dictates your immediate liquidity versus your exposure to future performance milestones.

The transaction highlights the specific complexities of a UK public company buying a private US entity. While the deal is marked as completed, the deferred portion introduces a layer of commercial risk that requires careful management. In such cross-border healthcare deals, change-of-control covenants in the target's existing contracts often trigger automatically, requiring immediate review by legal teams. Furthermore, the deferred consideration usually ties to specific post-closing targets, meaning the original founders remain financially exposed to the business performance for a set period. This is not merely a handover; it is a structured transition where the seller retains skin in the game.

Regulatory clearance for a deal of this size in the healthcare sector typically involves scrutiny from both UK and US competition authorities, though the specific thresholds for this 28 million USD transaction suggest it likely cleared standard filings without major anti-trust intervention. The use of deferred cash also implies that the buyer has secured the necessary funding or cash reserves to meet these future obligations, which is a positive sign of financial discipline. However, founders must ensure that the deferred terms are clearly defined to avoid disputes over how those targets are measured once the business is integrated into the larger group.

Your immediate action this week is to map out any change-of-control clauses in your own key customer or supplier contracts before you even sign a term sheet. Do not assume these will survive a sale automatically, as a UK buyer acquiring a US target will face immediate operational friction if critical agreements are terminated upon completion. Secure your supply chain and revenue base first, then negotiate the deferred payment structure to protect your upside without accepting vague performance metrics.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More strategic acquisition deals More from Venture Life Group PLC All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Not statedCompletedHealthcare

Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited

Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…

Buyer: Circle Health Holdings Limited
Target: CHC Healthcare Holdings Limited
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

11 August 2026ClearedHealthcare

Dolby Medical Home Respiratory Care Limited (Vivisol) to acquire Air Liquide Healthcare Limited’s home oxygen services business

Dolby Medical Home Respiratory Care Limited, trading as Vivisol, has agreed to acquire the home oxygen services business of Air Liquide Healthcare Limited in a strategic…

Buyer: Dolby Medical Home Respiratory Care Limited (Vivisol)
Target: Air Liquide Healthcare Limited’s home oxygen services business
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

10 August 2026Firm intentionHealthcare

RSLGH, LLC to acquire RYTHM, Inc.

RSLGH, LLC has agreed to acquire RYTHM, Inc., a healthcare company based in the United States, in a strategic acquisition valued at $109.5 million. The transaction invol…

Buyer: RSLGH, LLC
Target: RYTHM, Inc.
Deal value: USD 109,500,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

5 August 2026CompletedHealthcare

Ensysce Biosciences, Inc. to acquire Cy Biopharma, Inc.

Ensysce Biosciences, Inc. has agreed to acquire Cy Biopharma, Inc. in a strategic acquisition within the healthcare sector. The transaction was announced on 5 August 202…

Buyer: Ensysce Biosciences, Inc.
Target: Cy Biopharma, Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

31 July 2026Firm intentionHealthcare

Profusa, Inc. to acquire G3 Vision Labs Inc.

Profusa, Inc. has agreed to acquire G3 Vision Labs Inc. in a strategic acquisition within the healthcare sector. The transaction involves the exchange of shares as the p…

Buyer: Profusa, Inc.
Target: G3 Vision Labs Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

Buyer history